Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1084 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Sacubitril-valsartan for previously untreated chronic heart failure with reduced ejection fraction in children	Sacubitril-valsartan	Chronic heart failure	Cardiovascular System	2022	View \| Download
Sacubitril/valsartan for the treatment of post-acute myocardial infarction patients with left ventricular systolic dysfucntion and/or pulmonary congestion – first line	Entresto; LCZ 696 (fixed dose combination: Sacubitril; Valsartan)	Post-acute myocardial infarction (MI)	Cardiovascular System	2021	View \| Download
SAGE-547 for super-refractory status epilepticus	Brexanolone (SAGE-547; Zulresso)	Super-refractory status epilepticus (SRSE)	Neurology	2017	View \| Download
SAR443820 for treating amyotrophic lateral sclerosis (ALS)	SAR443820 (DNL788)	Amyotrophic lateral sclerosis	Neurology	2023	View \| Download
Sarilumab for treating Polyarticular-course Juvenile idiopathic arthritis in children and adolescents	Sarilumab	Juvenile idiopathic arthritis	Rheumatology	2023	View \| Download
Sarizotan for Respiratory Symptoms Associated Rett Syndrome	Sarizotan (EMD-128130)	Rett syndrome	Genetic Disorders , Neurology	2018	View \| Download
Savolitinib for MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma	Savolitinib (AZD6094)	Renal cell carcinoma (RCC)	Renal Cancer	2019	View \| Download
Sebetralstat for treating hereditary angioedema	Sebetralstat (KVD-900)	Hereditary angioedema (HAE)	Genetic Disorders , Immunology	2023	View \| Download
Secukinumab for enthesitis-related arthritis and juvenile psoriatic arthritis in children and adolescents from the age of 2 years	Secukinumab (Cosentyx; AIN457)	Enthesitis-related arthritis , Juvenile psoriatic arthritis	Rheumatology	2019	View \| Download
Secukinumab for hidradenitis suppurativa	Secukinumab (Cosentyx; AIN457)	Hidradenitis suppurativa (HS)	Dermatology	2021	View \| Download